Literature DB >> 1962796

Prediction of the antihypertensive response to enalapril.

P A Meredith1, R Donnelly, H L Elliott, C A Howie, J L Reid.   

Abstract

This study investigates the potential utility of a drug concentration-effect modelling approach to predict the long-term response to antihypertensive treatment with enalapril. Concentration-effect relationships were characterized in 13 subjects following a single dose of enalapril (20 mg) and for each individual the derived parameters were used to predict the steady-state blood pressure profile. The predicted responses (before dosing and 4 h after dosing) were in close agreement with the responses observed after 6 weeks. In individual patients, the observed and predicted blood pressure profiles over a 12 h period were compared. In six of the 13 subjects, there were statistically significant (P less than 0.05) prediction errors. However, in all but one of these patients the error was less than 10%, and for the group as a whole the mean prediction error was small and not statistically significant (-0.6 +/- 2.1 mmHg). The kinetic-dynamic parameters derived from observations of the first dose were used to simulate steady-state responses to several alternative doses and dose frequencies. A regimen of 10 mg twice daily increased the ratio of blood pressure at trough-to-peak response to 75 +/- 5% compared to 33 +/- 16% when 20 mg was given once daily. In addition, a twice-daily regimen reduced the coefficient of variation of the hourly average blood pressure. Thus, concentration-effect parameters derived from the first dose response to enalapril have potential not only for predicting long-term antihypertensive response, but also for optimizing dosage regimens for individual patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1962796     DOI: 10.1097/00004872-199012000-00003

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  10 in total

1.  ACE inhibition and AT(1) receptor blockers: efficacy and duration in hypertension.

Authors:  P A Meredith
Journal:  Heart       Date:  2000-09       Impact factor: 5.994

2.  The description and prediction of antihypertensive drug response: an individualised approach.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

Review 3.  ACE inhibitors for heart failure: a question of dose.

Authors:  J G Cleland; P A Poole-Wilson
Journal:  Br Heart J       Date:  1994-09

Review 4.  The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.

Authors:  J S Grundy; R T Foster
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

Review 5.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

Review 6.  Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview.

Authors:  R J MacFadyen; P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

Review 7.  Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors?

Authors:  F Zannad
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  Investigation of the biochemical effects of renin inhibition in normal volunteers treated by an ACE inhibitor.

Authors:  D Chauveau; T T Guyenne; F Cumin; G Chatellier; P Corvol; J Ménard
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

9.  A series of N-of-1 trials to assess the therapeutic interchangeability of two enalapril formulations in the treatment of hypertension in Addis Ababa, Ethiopia: study protocol for a randomized controlled trial.

Authors:  Chalachew Alemayehu; Geoffrey Mitchell; Abraham Aseffa; Alexandra Clavarino; James McGree; Jane Nikles
Journal:  Trials       Date:  2017-10-10       Impact factor: 2.279

10.  Long-acting tunable release of amlodipine loaded PEG-PCL micelles for tailored treatment of chronic hypertension.

Authors:  Nicola Di Trani; Hsuan-Chen Liu; Ruogu Qi; Dixita I Viswanath; Xuewu Liu; Corrine Ying Xuan Chua; Alessandro Grattoni
Journal:  Nanomedicine       Date:  2021-06-22       Impact factor: 6.096

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.